Although observational studies have reported associations between serum C-reactive protein (CRP) concentration and risks of lung, breast, and colorectal cancer, inconsistent or absent evidences were showed for other cancers. We conducted a pan-cancer analysis to comprehensively assess the role of CRP, including linearity and non-linearity associations.
Methods
We analyzed 420,964 cancer-free participants from UK Biobank cohort. Multivariable-adjusted Cox proportional hazards model was conducted to evaluate the observed correlation of CRP with overall cancer and 21 site-specific cancer risks. Furthermore, we performed linear and non-linear Mendelian randomization analyses to explore the potential causal relation between them.
Results
During a median follow-up period of 7.1 years (interquartile range: 6.3, 7.7), 34,979 incident cancer cases were observed. Observational analyses showed higher CRP concentration was associated with increased risk of overall cancer (hazard ratio (HR) = 1.02, 95% CI: 1.01, 1.02 per 1mg/L increase, P < 0.001). There was a non-linear association between CRP and overall cancer risk with inflection point at 3mg/L (false-discovery rate adjust (FDR-adjusted) Poverall < 0.001 and FDR-adjusted Pnon-linear < 0.001). For site-specific cancer, we observed positive linear associations for cancers of esophagus and stomach (FDR-adjusted Poverall < 0.050 and FDR-adjusted Pnon-linear > 0.050). In addition, we also observed three different patterns of non-linear associations, including “fast-to-low increase” (head and neck, colorectal, liver, lung, kidney cancer, and non-Hodgkin lymphoma), “increase-to-decrease” (breast cancer), and “decrease-to-platform” (chronic lymphocytic leukemia). Furthermore, the inflection points of non-linear association patterns were consistently at around 3mg/L. By contrast, there was no evidence for linear or non-linear associations between genetically predicted CRP and risks of overall cancer or site-specific cancers.
Conclusions
Our results indicated that CRP was a potential biomarker to assess risks of overall cancer and 12 site-specific cancers, while no association were observed for genetically-predicted CRP and cancer risks.
Meng Zhu and Zhimin Ma contributed equally to this work.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AIC
Akaike information criterion
BMI
Body mass index
CNS
Central nervous system
CLL
Chronic lymphocytic leukemia
CRP
C-reactive protein
FDR
False-discovery rate
HR
Hazard ratio
IQR
Interquartile range
LACE
Localized average causal effect
MR
Mendelian randomization
SNPs
Single nucleotide polymorphisms
wGRS
Weighted genetic risk score
Background
Inflammation has been demonstrated as the seventh hallmark of cancer [1]. It has been suggested that the state of chronic low-grade inflammation predisposed a person to cancer by building up an inflammatory microenvironment [2]. Although C-reactive protein (CRP) is a classical acute phase reactant protein from pentraxin family, a moderate increase of CRP level had been observed in chronic inflammatory states [3]. Previous studies have reported associations between serum CRP concentration and cancers of lung [4, 5], breast [6], and colorectal [7], while showing inconsistent or absent evidences for the associations of other cancer. This indicated the necessity of a pan-cancer analysis to systematically evaluate the associations of CRP and cancer risk, especially in prospective studies. In addition, the causal relationship between CRP and cancer risk remained to be explored due to the potential unmeasured confounders or reverse causality in observational studies.
Mendelian randomization (MR) analysis has been widely used to explore the causal associations between risk factors and diseases [8, 9]. Previous MR analysis has showed that the genetically elevated CRP concentration was probably to be a causal factor for gallbladder cancer [10], while not for cancers of colorectal [8], breast [11], or prostate [12]. The heritability of CRP was estimated to range between 25 and 40% [13]. However, only a small number of single nucleotide polymorphisms (SNPs) have been identified to construct the genetic instrument of CRP in previous studies [14, 15]. Recently, additional CRP-related susceptibility loci have been identified with the accumulation of sample size, which will help construct a more effective genetic instrumental variable [16].
Anzeige
Traditional MR analysis tested the hypothesis of linearity between exposure and outcome, while ignoring the possible non-linear relationship [17]. Recently, a new method was proposed to assess the potential non-linear J- or U-shape effects in MR analysis [17], which has been successfully used in the investigation of diastolic blood pressure and the risk of myocardial infarction [18]. The non-linear MR analysis took the strategy of conditioning on quantiles of instrumental variable and generated localized average causal effect (LACE) estimates. Hence, exploring the non-linear relationship between CRP concentration and cancer risk in observational studies and MR analysis, simultaneously, might provide new knowledge for understanding CRP concentration and cancer risk.
In this study, based on a large-scale prospective cohort study-the UK Biobank, we performed a pan-cancer analysis to assess the linear and non-linear associations between CRP and cancer risk. Furthermore, with the traditional MR and a state-of-the-art non-linear MR, we explored the linear and non-linear relationships between genetically predicted CRP and cancer risk simultaneously.
Methods
Study population
All data included in this analysis were obtained from UK Biobank. The UK Biobank is a large-scale cohort, including 502,507 participants recruited from 22 assessment centers throughout the UK during 2006–2010 [19]. All participants completed a written informed consent form, a self-completed touch-screen questionnaire, a brief computer-assisted interview, and physical measures. Meanwhile, biological samples including blood were collected through strict quality control during the baseline period from different centers [19].
In this study, we excluded 46,533 patients with cancer at baseline, 30,035 participants without CRP information, and 4975 individuals without genetic data. Finally, a total of 420,964 participants were included in this study.
Anzeige
Assessment of exposure, outcome, and covariates
The CRP concentration was measured by immunoturbidimetric-high sensitivity analysis on Beckman Coulter AU5800 at baseline, with a range from 0.08 to 79.96 mg/L. The outliers were capped by the 1st percentile (Q1) or 99th percentile (Q99) of CRP level. A special detail of collection and processing of blood sample has been described elsewhere [20].
Cancer outcomes were defined based on the ICD10 coding and obtained from the national cancer registry. The follow-up time referred to the period from baseline enrollment to the first diagnosis of cancer, the first registration of cancer or loss, or end of follow-up (31 October 2015 for Scotland and 31 March 2016 for England and Wales). After excluding site-specific cancer with less than 100 incident cases, we finally included overall cancer and 21 site-specific cancers in this study (Additional file 2: Table S1).
Variables that might affect the association between CRP and cancer risk based on previous studies were considered as covariates in our analysis, including age, family cancer history, body mass index (BMI), height, smoking status, alcohol use, and physical activity for both male and female, as well as menopausal, oral contraceptive use, and hormone replacement therapy for female [21]. Besides, we also included sex, ethnic, education, Townsend deprivation index, and assessment center as covariates. These covariates were collected using a touchscreen questionnaire or measured by trained staffs at baseline, and no covariates had more than 2.0% of missing values (Additional file 2: Table S2). The missing values on continued covariates were replaced with the sex-specific mean value of each variable. And missing values on categorical covariates were considered as “unknown” category.
Genotyping
Genome-wide genotyping was performed using the Affymetrix UK BiLEVE Axiom array or the Affymetrix UK Biobank Axiom array. The two arrays share 95% of the markers. Imputation was performed with SHAPEIT3 and IMPUTE3 based on merged UK10K and 1000 Genomes phase3 panels [22]. Markers with minor allele frequency > 0.001 and Info score > 0.3 were retained in UK Biobank. Detail information on genotype quality, quality control, and genotype imputation has been described in previous study [22].
Genetic instrument for serum CRP level
A total of 52 susceptibility loci associated with serum CRP concentration have been identified in a previous GWAS [16], which was used to construct the genetic instrument of CRP by calculating the weighted genetic risk score (wGRS). The genetic instrument was strongly associated with serum CRP concentration with an F statistic of 216 and could explain 2.6% of the variance of CRP in this study (Additional file 1). In addition, five SNPs associated with both colorectal cancer and serum CRP concentration were further excluded in the sensitivity analysis to evaluate the validity of the instruments (Table S3 in the Additional file 2).
Statistical analysis
Cox proportional hazards regression was conducted to assess the association between CRP and cancer risk. Schoenfeld residuals and log-log inspection were used to test the assumption of proportional hazards. The time scale in the Cox PH regression was from the enrolment until the time of cancer diagnosis, death, withdrawal from study, or the end of follow-up, whichever came first. We estimated the hazard ratio (HR) associated with CRP (per 1 mg/L increase) for each site-specific cancer in all eligible participants and re-evaluated the HRs by dividing participants into low CRP level (≤ 3mg/L) and high CRP level (>3 mg/L) [23]. We further applied restricted cubic spline analysis to explore the possibly non-linear association shapes between serum CRP concentration and cancer risk. To balance the best fitting and over fitting in the splines for cancer, the number of knots were tested from three to five, and we chose that with the lowest value of Akaike information criterion (AIC); if the same AIC was observed for different knots, the lowest number of knots was chosen [24]. Except for lung cancer (4 knots at the 5th, 35th, 65th, and 95th percentile of CRP), we fitted the models of overall cancer and other site-specific cancer with 3 knots at the 10th, 50th, and 90th percentile of CRP. We used a likelihood ratio test to calculate P-value for non-linearity by comparing the model with only a linear term against the model with linear and cubic spline terms [25]. We further performed subgroup analyses to assess potential effect modification by age, sex, and smoking status using likelihood ratio tests. To examine the robustness of our results, we performed several sensitivity analyses: (1) re-analysis the association between log-transformed CRP level and cancer risk, (2) exclusion or only inclusion of participants diagnosed with cancer within the first two follow-up to avoid the potential reverse causality, (3) exclusion of participants with CRP level of >10 mg/L to avoid the effect of acute serious infection, (4) additionally adjusted for cardiovascular disease and diabetes, and (5) additionally adjusted for regular use of aspirin and ibuprofen.
The potential linear and non-linear causal associations between CRP concentration and cancer risk were simultaneously evaluated in this study. To evaluate the potential linear associations, we performed a two-stage MR analysis. In the first stage, we estimate the fitted values using a regression of CRP against wGRS, and in second stage, the predicted value was further fitted in a Cox regression model with cancer risk. Covariates, including age at baseline, sex, and the top 10 genetic principal components, were adjusted in both stages. In addition, several sensitivity analyses were also performed in the analysis: (1) we re-estimated the causal associations between log-transformed CRP level and cancer risks, (2) two-stage MR was only conducted in participants of British ancestry, and (3) rs2794520, the strongest SNP in previous GWAS, was used as an instrument variable to minimize the possibility of introducing horizontal pleiotropy [16].
For non-linear MR analysis, the sample was stratified into three strata according to residual CRP (the CRP minus the genetically predicted CRP). Next, we assessed the exposure-outcome associations using the piecewise linear method within each stratum, by contributing a line piece whose gradient is the LACE [17]. Two tests were then applied for non-linear hypothesis: (1) a heterogeneity test using Cochran’s Q statistic to analyze the difference between the LACE estimates and (2) a trend test, which conducted a meta-regression of the LACE estimates against the mean value of the CRP in each stratum.
Anzeige
All analyses were performed with R (version 3.6.0), and the two-sided P value of <0.05 was considered as statistically significant. To avoid the inflation of false-positive findings, we calculated the false-discovery rate (FDR) adjusted P values across the main analyses. Linear and non-linear MR analyses were conducted using the “MendelianRandomization” and “nlmr” packages, respectively.
Results
Baseline characteristics
The baseline characteristics of participants are illustrated in Table 1. Out of 420,964 eligible participants, 34,979 incident cancer events were diagnosed during a median follow-up of 7.1 years (interquartile range, IQR: 6.3–7.7). Participants with incident cancer had higher CRP concentration (2.7 ± 3.6 mg/L) than those without incident cancer (2.4 ± 3.3 mg/L).
Table 1
Baseline characteristics of study participants by incident overall cancer
Overall (N=420,964)
No cancer (N=385,985)
Incident cancer (N=34,979)
CRP at baseline,(mg/L)
2.4 ± 3.3
2.4 ± 3.3
2.7 ± 3.6
Age at baseline,(years)
56.2 ± 8.1
55.9 ± 8.1
60.2 ± 6.8
Male,n(%)
197,223 (46.9)
178,749 (46.3)
18,474 (52.8)
Ethnic,n(%)
White
395,650 (94.0)
361,760 (93.7)
33,890 (96.9)
Asian
9994 (2.4)
9632 (2.5)
362 (1.0)
African
6829 (1.6)
6557 (1.7)
272 (0.8)
Mixed background
2551 (0.6)
2427 (0.6)
124 (0.4)
Unknown
5940 (1.4)
5609 (1.5)
331 (0.9)
Education,n(%)
No degree
278,328 (66.1)
254,225 (65.9)
24,103 (68.9)
Degree
137,610 (32.7)
127,166 (33.0)
10,444 (29.9)
Unknown
5026 (1.2)
4594 (1.1)
432 (1.2)
Townsend deprivation index
−1.3 ± 3.1
−1.3 ± 3.1
−1.5 ± 3.0
Standing height, (cm)
168.6 ± 9.3
168.6 ± 9.3
169.3 ± 9.1
BMI, (kg/m2)
27.4 ± 4.8
27.4 ± 4.8
27.6 ± 4.7
Smoking status,n(%)
Never
230,940 (54.9)
213,858 (55.4)
17,082 (48.8)
Previous
143,521 (34.1)
129,772 (33.6)
13,749 (39.3)
Current
44,385 (10.5)
40,431 (10.5)
3954 (11.3)
Unknown
2118 (0.5)
1924 (0.5)
194 (0.6)
Alcohol use,n(%)
Never
18,583 (4.4)
17,311 (4.5)
1272 (3.6)
Previous
14,892 (3.5)
13,547 (3.5)
1345 (3.9)
Current
386,411 (91.8)
354,112 (91.7)
32,299 (92.3)
Unknown
1078 (0.3)
1015 (0.3)
63 (0.2)
Physical activity (MET/week),n(%)
<600
63,447 (15.0)
58,199 (15.1)
5248 (15.0)
600–3000
252,403 (60.0)
231,494 (60.0)
20,909 (59.8)
≥3000
105,114 (25.0)
96,292 (24.9)
8822 (25.2)
Having family cancer history,n(%)
145,198 (34.5)
131,509 (34.1)
13,689 (39.1)
Menopausal,n(%)a
No
55,655 (24.9)
53,240 (25.7)
2,415 (14.6)
Yes
133,190 (59.5)
121,674 (58.7)
11,516 (69.8)
Not sure
34,209 (15.3)
31,665 (15.3)
2544 (15.4)
Unknown
687 (0.3)
657 (0.3)
30 (0.2)
Oral contraceptive use,n(%)a
Never
41,599 (18.6)
38,025 (18.4)
3574 (21.7)
Ever
181,103 (80.9)
168,223 (81.2)
12,880 (78.0)
Unknown
1039 (0.5)
988 (0.5)
51 (0.3)
Hormone replacement therapy,n(%)a
Never
138,909 (62.1)
130,148 (62.8)
8761 (53.1)
Ever
83,657 (37.4)
75,983 (36.7)
7674 (46.5)
Unknown
1175 (0.5)
1105 (0.5)
70 (0.4)
Assessment center,n(%)
East Midlands
28,471 (6.8)
26,106 (6.8)
2365 (6.8)
London
58,162 (13.8)
54,306 (14.1)
3856 (11.0)
North Eastern England
49,043 (11.7)
44,883 (11.6)
4160 (11.9)
North West England
88,420 (21.0)
80,906 (21.0)
7514 (21.5)
Scotland
55,745 (13.2)
50,767 (13.2)
4978 (14.2)
South East England
12,216 (2.9)
10,874 (2.8)
1342 (3.8)
South west England
36,372 (8.6)
33,252 (8.6)
3120 (8.9)
Wales
17,998 (4.3)
16,483 (4.3)
1515 (4.3)
West Midlands England
37,451 (8.9)
34,445 (8.9)
3006 (8.6)
Yorkshire and the Humber
37,086 (8.8)
33,963 (8.8)
3123 (8.9)
aAnalysis was only conducted among women
Data are presented as mean ± standard deviation for continuous variables and n (%) for categorical variables
Observational association evaluation
The increase of serum CRP concentration was associated with incident events of overall cancer (HR = 1.02, 95% CI: 1.01–1.02 per 1mg/L increase, P < 0.001). Consistently, similar associations were observed for cancers of head and neck, esophagus, stomach, colorectal, liver, lung, uterus, kidney, non-Hodgkin lymphoma, and multiple myeloma (Additional file 2: Table S4).
To explore potential non-linear associations between CRP concentration and cancer risk, we estimated the associations with restricted cubic spline analysis. As shown in Fig. 1, a non-linear association was also observed between CRP concentration and overall cancer risk with inflection point at 3mg/L (FDR-adjusted Poverall < 0.001, and FDR-adjusted Pnon-linear < 0.001). For site-specific cancer, we observed three different patterns of non-linear associations along with the increase of CRP concentration (FDR-adjusted Poverall < 0.05, and FDR-adjusted Pnon-linear < 0.05), including (1) “fast-to-low increase” of risks for cancers of head and neck, colorectal, liver, lung, kidney cancer, and non-Hodgkin lymphoma; (2) “increase-to-decrease” of risk for breast cancer; and (3) “decrease-to-platform” of risk for chronic lymphocytic leukemia (CLL). In addition, we also observed positive linear associations for cancers of esophagus and stomach along with the increase of CRP concentration (FDR-adjusted Poverall < 0.050, and FDR-adjusted Pnon-linear > 0.050). In sensitivity analyses, we observed a consistent inflection point of 3mg/L by exclusion of incident cancer cases diagnosed within the first 2 years of follow-up (Additional file 3: Figure S1). Furthermore, we also observed a non-linear association with inflection point at 1mg/L after log-transformed of CRP levels (Additional file 3: Figure S2).
Fig. 1
Analysis of the shape of the relationship between CRP and cancer outcomes using restricted cubic spline based on observational data. All P values in the figure are false-discovery rate adjusted P values. Adjusted for age, sex (female, male), ethnic (White, Asian, African, mixed background, unknown), education (no degree, degree, unknown), Townsend deprivation index, standing height, BMI, smoking status (never, previous, current, unknown), alcohol use (never, previous, current, unknown), physical activity (<600 MET/week, 600–3000 MET/week, ≥3000 MET/week), family cancer (no, yes), and assessment center. Additionally, adjusted for menopausal (no, yes, not sure, unknown), oral contraceptive use (never, ever, unknown), and hormone replacement therapy (never, ever, unknown) for female. CNS, central nervous system; CLL, chronic lymphocytic leukemia
×
Anzeige
Even though different non-linear association patterns were observed for site-specific cancer, the inflection points of the associations were consistently at around 3mg/L, which was in consistent with the risk stratification of cardiovascular disease by the American Heart Association [24]. Therefore, we further re-estimated the associations in participants of low CRP level (≤ 3mg/L) and high CRP level (>3 mg/L), respectively. Univariable analysis shows significant heterogeneities along with the increase of CRP between the two subgroups (Additional file 2: Table S5). After adjusting for covariates, statistically significant heterogeneities (FDR-adjusted Pheterogeneity < 0.05) of the association effects were also observed for overall cancer, colorectal, lung, and breast cancer (Table 2). Sensitivity analyses indicated that the associations were robust by re-evaluating the association between log-transformed CRP level and cancer risk (Additional file 2: Table S6), additionally adjusting for cardiovascular and diabetes diseases (Additional file 2: Table S7), additionally adjusting for the regular use of drugs that may affect the CRP concentration (Additional file 2: Table S8), excluding or only including individuals with incident cancer within the first two of follow-up (Additional file 2: Table S9 and S10), and excluding individuals with CRP > 10 mg/L (Additional file 2: Table S11).
Table 2
Hazard ratios (HRs) for cancer outcomes per 1 mg/L higher CRP concentration based on observation data
Low CRP (≤ 3mg/L)
High CRP (>3 mg/L)
FDR-adjusted Pheterogeneity
No (incident cases)
Person years
HR (95%CI)
P
No (incident cases)
Person years
HR (95%CI)
P
Overall cancer
327,031 (26,173)
2,237,479
1.04 (1.03,1.06)
<0.001
<0.001
93,933 (8,806)
635,846
1.01 (1.01,1.01)
<0.001
<0.001
Head & neck (C00–14)
301,209 (351)
2,137,461
1.08 (0.93,1.25)
0.318
0.663
85,283 (156)
603,797
1.02 (0.99,1.05)
0.180
0.482
Esophagus (C15)
301,201 (344)
2,137,476
1.14 (0.99,1.32)
0.078
0.434
85,273 (146)
603,701
1.04 (1.01,1.07)
0.014
0.217
Stomach (C16)
301,087 (229)
2,136,975
1.05 (0.87,1.26)
0.614
0.873
85,232 (106)
603,559
1.03 (0.99,1.07)
0.154
0.833
Colorectal (C18–20)
303,003 (2,145)
2,144,527
1.11 (1.04,1.18)
0.001
0.033
85,917 (791)
605,899
1.02 (1.00,1.03)
0.027
0.006
Liver (C22)
301,037 (179)
2,136,852
1.20 (0.98,1.47)
0.080
0.235
85,230 (103)
603,594
1.01 (0.97,1.05)
0.788
0.096
Gallbladder (C23–24)
300,952 (94)
2,136,473
0.87 (0.65,1.17)
0.351
0.873
85,172 (45)
603,354
0.90 (0.82,0.99)
0.035
0.808
Pancreas (C25)
301,268 (410)
2,137,813
1.14 (0.99,1.30)
0.066
0.163
85,286 (159)
603,798
0.99 (0.95,1.02)
0.510
0.052
Lung (C33–34)
301,995 (1,137)
2,140,855
1.26 (1.16,1.36)
<0.001
<0.001
85,882 (755)
606,121
1.03 (1.02,1.05)
<0.001
<0.001
Melanoma (C43)
301,966 (1,111)
2,140,358
0.98 (0.9,1.07)
0.655
0.663
85,437 (310)
604,460
1.01 (0.99,1.04)
0.238
0.464
Non-melanotic skin (C44)
309,450 (8,597)
2,170,575
1.01 (0.97,1.04)
0.729
0.945
87,430 (2,305)
612,401
1.01 (1.00,1.02)
0.128
0.945
Breast (C50)
160,803 (3,644)
1,130,896
1.07 (1.02,1.13)
0.003
0.007
51,446 (1,371)
361,233
0.99 (0.98,1.00)
0.137
0.001
Uterus (C54-55)
157,651 (491)
1,119,136
1.13 (1.00,1.28)
0.050
0.226
50,382 (306)
357,326
1.01 (0.99,1.04)
0.321
0.082
Ovary (C56)
157,548 (388)
1,118,715
1.12 (0.97,1.29)
0.126
0.304
50,223 (147)
356,717
1.00 (0.96,1.04)
0.993
0.138
Prostate (C61)
148,034 (4,337)
1,035,523
0.99 (0.95,1.03)
0.649
0.824
36,092 (1,043)
250,894
1.00 (0.99,1.01)
0.811
0.712
Kidney (C64)
301,320 (463)
2,137,990
1.13 (0.99,1.28)
0.066
0.477
85,362 (235)
604,047
1.05 (1.03,1.07)
<0.001
0.278
Bladder (C67)
301,270 (412)
2,137,591
1.05 (0.91,1.20)
0.524
0.819
85,281 (154)
603,785
1.01 (0.98,1.05)
0.394
0.670
CNS (C70–72)
301,185 (327)
2,137,370
1.14 (0.98,1.33)
0.092
0.154
85,232 (105)
603,587
0.96 (0.92,1.01)
0.113
0.037
Thyroid (C73)
301,031 (173)
2,136,726
1.07 (0.86,1.32)
0.553
0.819
85,179 (52)
603,385
1.01 (0.96,1.07)
0.617
0.656
Non-Hodgkin lymphoma (C82–85, 96)
301,634 (776)
2,139,208
1.08 (0.98,1.20)
0.123
0.477
85,447 (320)
604,276
1.02 (1.00,1.05)
0.040
0.282
Multiple myeloma (C90)
301,172 (315)
2,137,379
0.89 (0.76,1.05)
0.182
0.625
85,211 (84)
603,538
0.96 (0.91,1.02)
0.178
0.398
CLL (C91)
301,166 (308)
2,137,248
0.83 (0.70,0.98)
0.033
0.154
85,205 (78)
603,491
1.00 (0.95,1.05)
0.924
0.042
Adjusted for age, sex (female, male), ethnic (White, Asian, African, mixed background, unknown), education (no degree, degree, unknown), Townsend deprivation index, standing height, BMI, smoking status (never, previous, current, unknown), alcohol use (never, previous, current, unknown), physical activity (<600 MET/week, 600–3000 MET/week, ≥3000 MET/week), family cancer (no, yes), and assessment center
Further adjusted for menopausal (no, yes, not sure, unknown), oral contraceptive use (never, ever, unknown), and hormone replacement therapy (never, ever, unknown) for female
CNS central nervous system, CLL chronic lymphocytic leukemia
Based on CRP concentration, participants were divided into three groups according to American Heart Association: low (< 1.0 mg/L), intermediate (1.0 to 3.0 mg/L), and high (> 3.0 mg/L). Compared with individuals at low CRP concentration, those in the intermediate and high CRP concentration had a higher risk of overall cancer, with HRs of 1.05 (95%CI: 1.02, 1.07; P < 0.001) and 1.15 (95%CI: 1.12, 1.18; FDR-adjusted P < 0.001), respectively (Table 3). Similar association results were observed for cancers of head and neck, colorectal, liver, lung, breast, ovary, kidney, and non-Hodgkin lymphoma (FDR-adjusted Ptrend < 0.05). On the contrary, individuals at high CRP concentration were at decreased risks for multiple myeloma and CLL (FDR-adjusted Ptrend < 0.05). Subgroup analysis showed that there was an interaction between CRP and smoking status on risk for overall cancer, lung, uterus, and prostate cancer (Additional file 2: Table S12). Besides, findings from sensitivity analyses were almost consistent with the primary analysis (Additional file 2: Table S13, S14, S15 and S17). The associations of CRP and cancer risks became stronger by only including patients that were diagnosed within 2 years of follow-up, indicating the associations were true (Additional file 2: Table S16).
Table 3
Hazard ratios (HRs) for cancer outcomes among three CRP groups based on observation data (compared with low CRP (≤1 mg/L) group, the hazard ratio for cancer risk among average/high CRP groups (per 1 mg/L higher CRP concentration))
Low CRP (<1 mg/L)
Average CRP (1 to 3 mg/L)
High CRP (>3 mg/L)
FDR-adjusted Ptrend
No. (incident cases)
No. (incident cases)
HR (95%CI)
P
No (incident cases)
HR (95%CI)
P
Overall cancer
166,888 (12,380)
160,143 (13,793)
1.05 (1.02, 1.07)
0.001
<0.001
93,933 (8806)
1.15 (1.12, 1.18)
<0.001
<0.001
Head & neck (C00–14)
154,674 (166)
146,535 (185)
1.06 (0.85, 1.31)
0.617
0.006
85,283 (156)
1.46 (1.15, 1.85)
0.002
0.002
Esophagus (C15)
154,643 (136)
146,558 (208)
1.20 (0.96, 1.49)
0.115
0.064
85,273 (146)
1.31 (1.01, 1.68)
0.038
0.038
Stomach (C16)
154,605 (97)
146,482 (132)
1.10 (0.84, 1.44)
0.500
0.064
85,232 (106)
1.38 (1.02, 1.87)
0.034
0.035
Colorectal (C18–20)
155,467 (959)
147,536 (1186)
1.11 (1.02, 1.21)
0.019
<0.001
85,917 (791)
1.27 (1.14, 1.40)
<0.001
<0.001
Liver (C22)
154,584 (76)
146,453 (103)
1.10 (0.81, 1.50)
0.523
0.003
85,230 (103)
1.73 (1.25, 2.40)
0.001
0.001
Gallbladder (C23–24)
154,553 (45)
146,399 (49)
0.82 (0.54, 1.24)
0.344
0.818
85,172 (45)
1.06 (0.67, 1.68)
0.805
0.818
Pancreas (C25)
154,678 (170)
146,590 (240)
1.15 (0.94, 1.41)
0.164
0.212
85,286 (159)
1.18 (0.93, 1.50)
0.162
0.154
Lung (C33–34)
154,927 (419)
147,068 (718)
1.37 (1.21, 1.55)
<0.001
<0.001
85,882 (755)
2.08 (1.83, 2.36)
<0.001
<0.001
Melanoma (C43)
155,064 (559)
146,902 (552)
1.01 (0.89,1.14)
0.936
0.792
85,437 (310)
1.03 (0.89, 1.21)
0.661
0.684
Non-melanotic skin (C44)
158,800 (4294)
150,650 (4,303)
0.99 (0.95,1.04)
0.743
0.818
87,430 (2305)
0.99 (0.94, 1.05)
0.814
0.785
Breast (C50)
83,335 (1704)
77,468 (1940)
1.15 (1.08, 1.23)
<0.001
<0.001
51,446 (1371)
1.20 (1.11, 1.31)
<0.001
<0.001
Uterus (C54–55)
81,841 (210)
75,810 (281)
1.01 (0.84, 1.21)
0.957
0.116
50,382 (306)
1.20 (0.97, 1.47)
0.087
0.074
Ovary (C56)
81,804 (173)
75,744 (215)
1.27 (1.03, 1.56)
0.028
0.024
50,223 (147)
1.37 (1.07, 1.76)
0.014
0.011
Prostate (C61)
74,992 (2116)
73,042 (2221)
0.99 (0.93, 1.06)
0.832
0.221
36,092 (1043)
0.94 (0.87, 1.02)
0.134
0.171
Kidney (C64)
154,689 (181)
146,631 (282)
1.26 (1.04, 1.53)
0.018
<0.001
85,362 (235)
1.64 (1.33, 2.03)
<0.001
<0.001
Bladder (C67)
154,689 (181)
146,581 (231)
1.01 (0.83, 1.23)
0.929
0.562
85,281 (154)
1.09 (0.87, 1.38)
0.447
0.460
CNS (C70–72)
154,662 (154)
146,523 (173)
1.11 (0.89, 1.40)
0.346
0.185
85,232 (105)
1.23 (0.94, 1.62)
0.129
0.126
Thyroid (C73)
154,590 (82)
146,441 (91)
1.09 (0.80, 1.49)
0.596
0.818
85,179 (52)
0.93 (0.63, 1.38)
0.711
0.789
Non-Hodgkin lymphoma (C82–85, 96)
154,862 (354)
146,772 (422)
1.14 (0.99, 1.32)
0.078
<0.001
85,447 (320)
1.53 (1.30, 1.81)
<0.001
<0.001
Multiple myeloma (C90)
154,670 (163)
146,502 (152)
0.82 (0.65, 1.03)
0.082
0.058
85,211 (84)
0.74 (0.55, 0.98)
0.039
0.029
CLL (C91)
154,675 (167)
146,491 (141)
0.74 (0.58, 0.93)
0.010
0.015
85,205 (78)
0.69 (0.51, 0.92)
0.012
0.006
Adjusted for age, sex (female, male), ethnic (White, Asian, African, mixed background, unknown), education (no degree, degree, unknown), Townsend deprivation index, standing height, BMI, smoking status (never, previous, current, unknown), alcohol use (never, previous, current, unknown), physical activity (<600 MET/week, 600–3000 MET/week, ≥3000 MET/week), family cancer (no, yes), and assessment center. Additionally adjusted for menopausal (no, yes, not sure, unknown), oral contraceptive use (never, ever, unknown), hormone replacement therapy (never, ever, unknown) for female. CNS, central nervous system; CLL, chronic lymphocytic leukemia
Mendelian randomization analyses
As shown in Fig. 2, there were no linear associations between genetically predicted CRP concentration and risk of overall cancer, as well as site-specific cancer (FDR-adjusted P > 0.05). Besides, similar results were also observed in the sensitivity analyses of re-estimating the association between log-transformed CRP concentration and cancer risks (Additional file 3: Figure S3), re-evaluating in individuals of genetically confirmed British ancestry (Additional file 3: Figure S4), or using rs2794520 as an instrument variable (Additional file 3: Figure S5). Furthermore, no evidences of non-linear causal effects were observed between genetically predicted CRP concentration and risk of overall cancer or site-specific cancer (Fig. 3).
Fig. 2
The casual relationship between the CRP and cancer outcomes using linear MR analysis. Adjusted for age, sex (female, male), BMI, smoking status (never, previous, current, unknown), and top ten genetic principal components, and chip. CNS, central nervous system; CLL, chronic lymphocytic leukemia
Fig. 3
Shape of casual relationship between CRP and cancer outcomes using the piecewise linear non-linear MR method. All P values in the figure are false-discovery rate adjusted P values. Adjusted for age, sex (female, male), BMI, smoking status (never, previous, current, unknown), top ten principal components of ancestry, and genotyping batch. CNS, central nervous system; CLL, chronic lymphocytic leukemia
×
×
Discussion
The role of inflammation in tumorigenesis is now generally accepted, but in which a direct causal relationship has yet not been proven [25]. In the present study, based on a large-scale prospective cohort study, we found elevated CRP concentration at baseline were associated with increased risk of incident cancer events during the follow-up. For site-specific cancer, positive associations were also observed for cancers of head and neck, esophagus, stomach, colorectal, liver, lung, breast, kidney cancer, and non-Hodgkin lymphoma, while negative association was observed for CLL. Although we observed three different patterns of non-linear associations between CRP concentration and site-specific cancers risks, obvious inflection points were observed at 3mg/L, and 1mg/L after log-transformed, which were in consistent with the findings for cardiovascular disease [24]. However, both linear and non-linear MR analysis demonstrated no associations between genetically predicted CRP and the risk of cancer.
Anzeige
Thus far, several hypotheses have been proposed to explain the potential mechanisms of the associations between elevated CRP concentration and risk of cancer: (1) tumor tissue would cause inflammation and thus increase serum level of CRP; (2) tumor cells could produce various cytokines and chemokines that stimulate CRP production in the liver; (3) CRP was a part of a host immune response to tumor cells; (4) CRP is a marker of chronic inflammation, which would promote carcinogenesis by creating an attractive environment; and (5) CRP could be acted as an internal exposure marker, which reflected the aging state of the body [26‐28].
Inconsistent associations have been reported between CRP and cancer risk in previous prospective cohort studies [29‐31]. Our results were in consistent with that from Danish cohort study and EPIC-Heidelberg Study, which demonstrated associations for overall cancer, lung cancer, and colorectal cancer [26, 27]. Moreover, our research further extended the positive associations to cancers of head and neck, liver, kidney, and non-Hodgkin lymphoma. Although CRP had been reported as a poor prognostic factor of CLL [32, 33], our results identified negative associations between CRP and incident cancer events of CLL during the follow-up, which might indicate preclinical patients had been undergoing immune dysfunction [34]. No associations have been reported for the associations between CRP concentration and breast cancer [35‐37], which were consistent with our tests of linear associations. Interestingly, our results further demonstrated a non-linear “increase-to-decrease” association pattern between CRP concentration and the breast cancer, which showed statistically significant heterogeneities for the associations between low (≤ 3mg/L) and high (> 3mg/L) CRP groups. The biological mechanisms underlying this special association pattern remain to be further studied.
In risk stratification of cardiovascular disease, the groups of low risk (< 1.0 mg/L), average risk (1.0 to 3.0 mg/L), and high risk (> 3.0 mg/L) approximately correspond to tertiles of CRP in the general adult population, which were derived from more than 40,000 persons in more than 15 populations [24]. In our study, we also observed an inflection point of the association between CRP and cancer risk at 3mg/L in different non-linear association patterns. After log-transformed, we also observed an inflection point at 1mg/L. This was probably because log-transformed can get a higher resolution for data with less than 1, but lower resolution for data with lager than 1. Unsurprisingly, the association pattern after log-transformed was obviously different from that of initial CRP level (Additional file 3: Figure S1 and Figure S2), this was probably because the meaning of the X-axis has been changed after log-transformed (i.e., 1 corresponding to 2.7mg/L, while 2 corresponding to 7.4 mg/L). It was especially worth noting that the increase of risk is more pronounced among individuals of low CRP group (<3mg/L), which highlighted the important role of chronic low-grade inflammation in carcinogenesis [28].
Although observational analysis showed significant associations between CRP concentration and incident cancer risk in the prospective cohort, MR analysis did not support the causal relationship. Similar discrepancy between the observational and MR analyses had been reported for breast cancer, colorectal cancer, prostate cancer, and lung cancer [8, 11, 12, 38]. In the observational analysis, potential confounding factors have been fully adjusted in the main and sensitivity analysis; moreover, similar associations were observed after excluding patients diagnosed within 2 years of follow-up. This indicated the discrepancy was not likely to be biased by confounding or reverse causality. Therefore, we hold the opinion that the CRP was probably not the cause of cancer itself, but acted as a response marker of environmental risk factors (i.e., smoking, air pollutions, and aging), which can cause chronic low-grade inflammation. However, this needed to be further evaluated as only 2.6% of the variance of CRP can be explained by the genetic instrumental variable.
The main advantage of this study lies in a comprehensive analysis, including both observational analysis and MR analysis, of the associations between CRP and overall cancer risk, as well as site-specific cancer. However, we also acknowledge several limitations of this study. First, CRP concentration was assessed on a single measure at baseline, and changes during the follow-up may have an effect on risk evaluation. Second, although there was a strong association between genetic instrumental variable and CRP concentration, these variants only explain a small proportion of variance in CRP concentration. Third, CRP is only one of the inflammatory markers, and a recent study has reported that genetically predicted circulating concentrations of several inflammatory-related cytokines were associated with the risk of breast, endometrial, lung, ovarian, and prostate cancer [39]. Fourth, evidences have indicated the poor representativeness of subjects in UK Biobank because of low participation and healthy volunteer bias; therefore, further studies are warranted to evaluate to what degree our findings may be generalized to the general population [40]. Fifth, most of the participants were of British ancestry in our study, which may limit the generalizability of our findings to other populations. Hence, these findings should be further validated in more diverse populations.
Conclusions
Based on a large-scale prospective cohort study, we demonstrated a positive association between CRP concentration and overall cancer risk, as well as nine site-specific cancers. Although we observed three non-linear association patterns between CRP concentration and site-specific cancers, the inflection points were at 3mg/L of CRP concentration, and at 1mg/L after log-transformed, consistently. However, no causal relationship was observed in the linear and non-linear MR analysis. These findings collectively indicated that CRP was a potential biomarker for cancer risk stratification, which might also take 1mg/L and 3mg/L as cutoff points.
Acknowledgements
This study was conducted using the UK Biobank resource. We would like to thank all participants and the UK Biobank team for their contribution.
Declarations
Ethics approval and consent to participate
The UK Biobank study was approved by the National Research Ethics Service Committee North West-Haydock. And each participant gave their informed written consent. Resource data were obtained under Application Number 82535.
Consent for publication
Not applicable.
Competing interests
The authors declare no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
